CSL Behring Canada Secures Public Reimbursement for HEMGENIX through LOI with PCPA
CSL Behring Canada has secured a Letter of Intent with the Public Pharmaceutical Agency to reimburse its product HEMGENIX, marking a significant step towards broader access to the therapeutic product.
2 minutes to read


